These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

575 related articles for article (PubMed ID: 34746488)

  • 1. Zolpidem: Efficacy and Side Effects for Insomnia.
    Edinoff AN; Wu N; Ghaffar YT; Prejean R; Gremillion R; Cogburn M; Chami AA; Kaye AM; Kaye AD
    Health Psychol Res; 2021; 9(1):24927. PubMed ID: 34746488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Main neuroendocrine features and therapy in primary sleep troubles.
    Amihăesei IC; Mungiu OC
    Rev Med Chir Soc Med Nat Iasi; 2012; 116(3):862-6. PubMed ID: 23272543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Daridorexant in Older and Younger Adults with Insomnia Disorder: A Secondary Analysis of a Randomised Placebo-Controlled Trial.
    Fietze I; Bassetti CLA; Mayleben DW; Pain S; Seboek Kinter D; McCall WV
    Drugs Aging; 2022 Oct; 39(10):795-810. PubMed ID: 36098936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insomnia in Elderly Patients: Recommendations for Pharmacological Management.
    Abad VC; Guilleminault C
    Drugs Aging; 2018 Sep; 35(9):791-817. PubMed ID: 30058034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Sleep disorders in patients with a neurocognitive disorder].
    Moderie C; Carrier J; Dang-Vu TT
    Encephale; 2022 Jun; 48(3):325-334. PubMed ID: 34916075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review of Safety and Efficacy of Sleep Medicines in Older Adults.
    Schroeck JL; Ford J; Conway EL; Kurtzhalts KE; Gee ME; Vollmer KA; Mergenhagen KA
    Clin Ther; 2016 Nov; 38(11):2340-2372. PubMed ID: 27751669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zolpidem's use for insomnia.
    Monti JM; Spence DW; Buttoo K; Pandi-Perumal SR
    Asian J Psychiatr; 2017 Feb; 25():79-90. PubMed ID: 28262178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Psychological and Medication Therapies for Insomnia on Daytime Functions: A Randomized Clinical Trial.
    Morin CM; Chen SJ; Ivers H; Beaulieu-Bonneau S; Krystal AD; Guay B; Bélanger L; Cartwright A; Simmons B; Lamy M; Busby M; Edinger JD
    JAMA Netw Open; 2023 Dec; 6(12):e2349638. PubMed ID: 38153735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term efficacy and safety of zolpidem extended-release 12.5 mg, administered 3 to 7 nights per week for 24 weeks, in patients with chronic primary insomnia: a 6-month, randomized, double-blind, placebo-controlled, parallel-group, multicenter study.
    Krystal AD; Erman M; Zammit GK; Soubrane C; Roth T;
    Sleep; 2008 Jan; 31(1):79-90. PubMed ID: 18220081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Zolpidem: an update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia.
    Holm KJ; Goa KL
    Drugs; 2000 Apr; 59(4):865-89. PubMed ID: 10804040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insomnia in the elderly: a review for the primary care practitioner.
    Ancoli-Israel S
    Sleep; 2000 Feb; 23 Suppl 1():S23-30; discussion S36-8. PubMed ID: 10755805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Zolpidem extended-release: a single insomnia treatment option for sleep induction and sleep maintenance symptoms.
    Barkin RL
    Am J Ther; 2007; 14(3):299-305. PubMed ID: 17515707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Newer hypnotic drugs for the short-term management of insomnia: a systematic review and economic evaluation.
    Dündar Y; Boland A; Strobl J; Dodd S; Haycox A; Bagust A; Bogg J; Dickson R; Walley T
    Health Technol Assess; 2004 Jun; 8(24):iii-x, 1-125. PubMed ID: 15193209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Zaleplon: a review of its use in the treatment of insomnia.
    Dooley M; Plosker GL
    Drugs; 2000 Aug; 60(2):413-45. PubMed ID: 10983740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sleep latency is shortened during 4 weeks of treatment with zaleplon, a novel nonbenzodiazepine hypnotic. Zaleplon Clinical Study Group.
    Elie R; Rüther E; Farr I; Emilien G; Salinas E
    J Clin Psychiatry; 1999 Aug; 60(8):536-44. PubMed ID: 10485636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In the Zzz zone: the effects of Z-drugs on human performance and driving.
    Gunja N
    J Med Toxicol; 2013 Jun; 9(2):163-71. PubMed ID: 23456542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Sleep disorders and hypnotic agents: medical, social and economical impact].
    Touitou Y
    Ann Pharm Fr; 2007 Jul; 65(4):230-8. PubMed ID: 17652991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sleep and residual sedation after administration of zaleplon, zolpidem, and placebo during experimental middle-of-the-night awakening.
    Zammit GK; Corser B; Doghramji K; Fry JM; James S; Krystal A; Mangano RM
    J Clin Sleep Med; 2006 Oct; 2(4):417-23. PubMed ID: 17557470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zolpidem for insomnia.
    Greenblatt DJ; Roth T
    Expert Opin Pharmacother; 2012 Apr; 13(6):879-93. PubMed ID: 22424586
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 29.